Cargando…

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muffly, Lori, Yin, Jun, Jacobson, Sawyer, Wall, Anna, Quiroz, Elisa, Advani, Anjali S., Luger, Selina M., Tallman, Martin S., Litzow, Mark R., Foster, Matthew C., Erba, Harry P., Appelbaum, Frederick R., Larson, Richard A., Keegan, Theresa H.M., Stock, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327550/ https://www.ncbi.nlm.nih.gov/pubmed/35838753 http://dx.doi.org/10.1182/bloodadvances.2022007197

Ejemplares similares

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
por: Rangel-Patiño, Juan, et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Sugiura, Isamu, et al.
Publicado: (2022)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
por: Johnsrud, Andrew, et al.
Publicado: (2021)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
por: Jacobson, Caron A., et al.
Publicado: (2023)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients
por: Mead, Monica, et al.
Publicado: (2022)

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
por: Allen, Pamela B., et al.
Publicado: (2022)

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
por: Saygin, Caner, et al.
Publicado: (2022)

Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia
por: Muffly, Lori, et al.
Publicado: (2020)

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
por: Perl, Alexander E., et al.
Publicado: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Hematologic complications with age in Shwachman-Diamond syndrome
por: Furutani, Elissa, et al.
Publicado: (2022)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023)

2198: Gender differences in the pharmacology of buprenorphine sublingual tablets in Hispanics/Latinos: An underrepresented population
por: Ivelisse Santiago, Darlene, et al.
Publicado: (2018)

Tuberculosis presentation and outcomes in older Hispanic adults from Tamaulipas, Mexico
por: Medrano, Belinda A., et al.
Publicado: (2023)

Ethnicity Influences Risk of Inflammatory Bowel Disease (IBD)-Associated Colon Cancer: A Cross-sectional Analysis of Dysplasia Prevalence and Risk Factors in Hispanics and Non-Hispanic Whites With IBD
por: Damas, Oriana M, et al.
Publicado: (2021)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial
por: Law, Zhe Kang, et al.
Publicado: (2021)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
por: Barnkob, Mike Bogetofte, et al.
Publicado: (2020)

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Hoiland, Ryan L., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sh7it5ihnr43dhb33vs425t0hm